Evidence map›Paper›PMID 36722972›Full record

ArticleJournal of virology2023

SARS-CoV-2 Uses Nonstructural Protein 16 To Evade Restriction by IFIT1 and IFIT3.

Craig Schindewolf, Kumari Lokugamage, Michelle N Vu, Bryan A Johnson, Dionna Scharton, Jessica A Plante, Birte Kalveram, Patricia A Crocquet-Valdes, Stephanea Sotcheff, Elizabeth Jaworski and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. ACS medicinal chemistry letters · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Craig SchindewolfDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Kumari LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Michelle N VuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Dionna SchartonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Birte KalveramDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Patricia A Crocquet-ValdesDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Stephanea SotcheffDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Elizabeth JaworskiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
Rojelio E AlvaradoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Kari DebbinkDepartment of Microbiology and Immunology, Johns Hopkins University, Baltimore, Maryland, USA.
Matthew D DaughertyDepartment of Molecular Biology, University of California, San Diego, California, USA.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Andrew L RouthInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-2874-5990
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0001-8803-7606
The University of Texas Medical Branch at Galveston · USJohns Hopkins University · USUniversity of California San Diego · US

Funding

Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SARKO, CHRISTOPHER · 2022 to 2023
$75.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Pathogen-driven evolution of innate antiviral defense mechanismsR35GM133633 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Matthew Daugherty · 2019 to 2026
$3.3M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400NIAID NIH HHS R24 AI120942NIAID NIH HHS T32 AI007526NIAID NIH HHS T32 AI060549NIAID NIH HHS U19 AI171413NIGMS NIH HHS R35 GM133633
6 · The paper itself

Abstract

Understanding the molecular basis of innate immune evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important consideration for designing the next wave of therapeutics. Here, we investigate the role of the nonstructural protein 16 (NSP16) of SARS-CoV-2 in infection and pathogenesis. NSP16, a ribonucleoside 2'-

Indexed as

Adaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsSARS-CoV-2Viral Nonstructural ProteinsAnimalsCOVID-19CricetinaeInterferon Type IMethyltransferasesRNA-Binding ProteinsAdaptor Proteins, Signal TransducingInterferon Type IIntracellular Signaling Peptides and ProteinsMethyltransferasesNSP16 protein, SARS-CoV-2RNA-Binding ProteinsViral Nonstructural Proteins2'-O-methyltransferaseantiviral agentscoronavirusIFIT1IFIT3interferon-stimulated geneNSP16SARS-CoV-2

Identifiers

PMID36722972
PMCPMC9973020
OpenAlexW4318754417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.